Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Animal models of Parkinson's disease progression.

Meredith GE, Sonsalla PK, Chesselet MF.

Acta Neuropathol. 2008 Apr;115(4):385-98. doi: 10.1007/s00401-008-0350-x. Epub 2008 Feb 14. Review.

2.

Genetic animal models of Parkinson's disease.

Dawson TM, Ko HS, Dawson VL.

Neuron. 2010 Jun 10;66(5):646-61. doi: 10.1016/j.neuron.2010.04.034. Review.

3.

Advances in the genetics of Parkinson's disease.

Rosner S, Giladi N, Orr-Urtreger A.

Acta Pharmacol Sin. 2008 Jan;29(1):21-34. Review.

4.

A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice.

Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR.

Neurotherapeutics. 2012 Apr;9(2):297-314. doi: 10.1007/s13311-012-0104-2. Review.

5.
6.

Transgenic mouse models of Parkinson's disease and Huntington's disease.

Skaper SD, Giusti P.

CNS Neurol Disord Drug Targets. 2010 Aug;9(4):455-70. Review.

PMID:
20522011
7.

Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis.

Carvey PM, Punati A, Newman MB.

Cell Transplant. 2006;15(3):239-50. Review.

PMID:
16719059
8.

Toxin models of mitochondrial dysfunction in Parkinson's disease.

Martinez TN, Greenamyre JT.

Antioxid Redox Signal. 2012 May 1;16(9):920-34. doi: 10.1089/ars.2011.4033. Epub 2011 Jul 12. Review.

9.

Disease model: Parkinson's disease.

Shimohama S, Sawada H, Kitamura Y, Taniguchi T.

Trends Mol Med. 2003 Aug;9(8):360-5. Review.

PMID:
12928038
10.

Parkinson's disease: Autoimmunity and neuroinflammation.

De Virgilio A, Greco A, Fabbrini G, Inghilleri M, Rizzo MI, Gallo A, Conte M, Rosato C, Ciniglio Appiani M, de Vincentiis M.

Autoimmun Rev. 2016 Oct;15(10):1005-11. doi: 10.1016/j.autrev.2016.07.022. Epub 2016 Aug 4. Review.

PMID:
27497913
11.

Evaluation of animal models of Parkinson's disease for neuroprotective strategies.

Emborg ME.

J Neurosci Methods. 2004 Oct 30;139(2):121-43. Review.

PMID:
15488225
12.

In vivo microdialysis in Parkinson's research.

Di Giovanni G, Esposito E, Di Matteo V.

J Neural Transm Suppl. 2009;(73):223-43. Review.

PMID:
20411781
13.

Assessing neuroprotection in Parkinson's disease: from the animal models to molecular neuroimaging in vivo.

Ceravolo R, Sgadò P, Frosini D, Corsini GU.

J Neural Transm Suppl. 2006;(71):133-41. Review.

PMID:
17447424
14.

Why have we failed to achieve neuroprotection in Parkinson's disease?

Olanow CW, Kieburtz K, Schapira AH.

Ann Neurol. 2008 Dec;64 Suppl 2:S101-10. doi: 10.1002/ana.21461. Review.

PMID:
19127580
15.

Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?

Bogaerts V, Theuns J, van Broeckhoven C.

Genes Brain Behav. 2008 Mar;7(2):129-51. Epub 2007 Aug 3. Review.

16.

An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions.

Johnson ME, Bobrovskaya L.

Neurotoxicology. 2015 Jan;46:101-16. doi: 10.1016/j.neuro.2014.12.002. Epub 2014 Dec 13. Review.

PMID:
25514659
17.
18.

In vivo gene delivery for development of mammalian models for Parkinson's disease.

Ulusoy A, Bjorklund T, Hermening S, Kirik D.

Exp Neurol. 2008 Jan;209(1):89-100. Epub 2007 Sep 22. Review.

PMID:
18028909
19.

Parkinson's disease: genetic versus toxin-induced rodent models.

Terzioglu M, Galter D.

FEBS J. 2008 Apr;275(7):1384-91. doi: 10.1111/j.1742-4658.2008.06302.x. Epub 2008 Feb 12. Review.

20.

Genetic mouse models of parkinsonism: strengths and limitations.

Fleming SM, Fernagut PO, Chesselet MF.

NeuroRx. 2005 Jul;2(3):495-503. Review.

Supplemental Content

Support Center